open access

Vol 49, No 1 (2018)
ORIGINAL RESEARCH ARTICLE
Published online: 2018-03-30
Submitted: 2017-06-30
Get Citation

Study of CD25 expression on leukemic cells: a prognostic factor in acute myeloid leukemia

Amina H Hassab, Dalia A Nafea, Rania S Swelem, Basma M Ghazal
DOI: 10.2478/ahp-2018-0004
·
Acta Haematol Pol 2018;49(1):20-27.

open access

Vol 49, No 1 (2018)
ORIGINAL RESEARCH ARTICLE
Published online: 2018-03-30
Submitted: 2017-06-30

Abstract

Background

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by a clonal expansion of myeloid blasts. Treatment strategies of patients with AML are based on various prognostic factors, including age and performance status of the patient, as well as cytogenetic and molecular characteristics of the leukemic clone.

Our aim was to study the expression of cluster of differentiation (CD)25 in adult Egyptian patients with newly diagnosed AML and to assess its prognostic relevance.

Methods

This study was conducted on 50 newly diagnosed AML patients at the Hematology Unit, Internal Medicine Department, Alexandria Main University Hospital. All patients were subjected to full history taking, thorough clinical examination, and laboratory investigations, including detection of CD25 expression on blast cells by flow cytometry. Conventional karyotyping was done on 11 patients at the time of diagnosis.

Results

In our study group, 12 patients were positive for CD25 expression, and this positivity was associated with worse overall survival and shorter leukemia-free survival. On evaluating the response to treatment among CD25-positive AML patients with normal karyotype, they had lower complete remission rates and higher relapse and death rates.

Conclusions

Expression of CD25 in AML patients at presentation can be considered a poor independent prognostic factor.

Abstract

Background

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by a clonal expansion of myeloid blasts. Treatment strategies of patients with AML are based on various prognostic factors, including age and performance status of the patient, as well as cytogenetic and molecular characteristics of the leukemic clone.

Our aim was to study the expression of cluster of differentiation (CD)25 in adult Egyptian patients with newly diagnosed AML and to assess its prognostic relevance.

Methods

This study was conducted on 50 newly diagnosed AML patients at the Hematology Unit, Internal Medicine Department, Alexandria Main University Hospital. All patients were subjected to full history taking, thorough clinical examination, and laboratory investigations, including detection of CD25 expression on blast cells by flow cytometry. Conventional karyotyping was done on 11 patients at the time of diagnosis.

Results

In our study group, 12 patients were positive for CD25 expression, and this positivity was associated with worse overall survival and shorter leukemia-free survival. On evaluating the response to treatment among CD25-positive AML patients with normal karyotype, they had lower complete remission rates and higher relapse and death rates.

Conclusions

Expression of CD25 in AML patients at presentation can be considered a poor independent prognostic factor.

Get Citation

Keywords

acute myeloid leukemia; prognosis; CD25 expression; cytogenetics; flow cytometry

About this article
Title

Study of CD25 expression on leukemic cells: a prognostic factor in acute myeloid leukemia

Journal

Acta Haematologica Polonica

Issue

Vol 49, No 1 (2018)

Pages

20-27

Published online

2018-03-30

DOI

10.2478/ahp-2018-0004

Bibliographic record

Acta Haematol Pol 2018;49(1):20-27.

Keywords

acute myeloid leukemia
prognosis
CD25 expression
cytogenetics
flow cytometry

Authors

Amina H Hassab
Dalia A Nafea
Rania S Swelem
Basma M Ghazal

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl